Abstract
Lipid nanoparticles（LNPs） have long been employed as a delivery platform for functional nucleic acids. However, recent advances in chemical modification technologies have drawn increasing attention to conjugate-based delivery systems, in which ligands are directly conjugated to nucleic acids. With the exception of N-acetylgalactosamine（GalNAc）, however, few ligands have demonstrated broad utility, and the number of successful reports remains limited. In particular, there is a strong unmet need for ligands capable of mediating delivery to organs other than the liver. This review focuses on “Antibody–Nucleic acid Conjugate,” which utilize antibodies as ligands that possess high specificity and stability and potentially enable targeted delivery to a variety of tissues. We summarize the progress of research efforts aimed at achieving nucleic acid delivery to antibody-accumulating tissues.
